Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...
Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...
Managing patients with Parkinson's disease should be viewed as part of a hospital CMO's responsibility for patient safety and ...
A drug that blocks a key receptor linked with blood pressure has shown promise recovering memory in models of vascular ...
A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...
Critically, they find that immune challenge is ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating ...
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...